AI assistant
Acumen Pharmaceuticals, Inc. — Director's Dealing 2021
Jul 1, 2021
34208_dirs_2021-06-30_a1c970b1-001e-45da-af59-5f49a6d24fc6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-06-30
Reporting Person: Siemers Eric (Chief Medical Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $0.72 | 2029-03-01 | Common Stock (186800) | Direct | |
| Stock Option (Right to Buy) | $1.19 | 2031-01-03 | Common Stock (310989) | Direct |
Footnotes
F1: The shares underlying the option vest and become exercisable in 36 equal monthly installments beginning on October 19, 2018, such that the option shall be fully vested on October 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on each such date.
F2: 25% of the shares underlying the option shall vest and become exercisable on January 1, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.